Long-term Surveillance of Low-risk PCa a Valid Option
the Renal and Urology News take:
A new study reveals favorable long-term outcomes for active surveillance of lower risk prostate cancer.
During a 10- to 15-year follow-up period, researchers found just 1.5% reported cases of prostate cancer metastasis and 1.3% reported deaths from the disease among a cohort of 993 men with lower risk prostate cancer on active surveillance.
In this group, mortality from other causes was 9.2 times greater than the risk of dying from prostate cancer. In light of these findings, published in the Journal of Clinical Oncology, active surveillance seems a safe option in select patients.
New imaging techniques and molecular biomarkers might help determine which patients should be considered for active surveillance.
In the study, treatment was offered to patients for a prostate-specific antigen (PSA) doubling time of less than 3 years, Gleason score progression, or unequivocal clinical progression.
Active Surveillance of Low-risk Prostate Cancer a Good Option
1. In a cohort of more than 900 low-risk prostate cancer patients followed for up to 15 years, 2.8% of patients developed metastatic disease and 1.5% died of prostate cancer.
2. The relative likelihood of dying from other causes compared to dying from prostate cancer death in this cohort was 9.2 to 1.
Evidence Rating Level: 2 (Good)
Study Rundown: Prostate cancer is the most common malignancies in men, with a lifetime risk of 1 in 7. Active surveillance (AS) is the process of forgoing initial definitive treatment for delayed definitive intervention when specific signs of disease progression has occurred.
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
Renal and Urology News Articles
- Residual Kidney Function Predicts Mortality in CKD-MBD
- Renal, Bladder Cancer Linked to Physical Inactivity
- Pure Bladder Cancer Variants Linked to Worse Survival After RC
- Keytruda Approved for All Cancers With Specific Genetic Biomarker
- Combined Urinary Testing Helps Detect Aggressive PCa, Avoid Biopsy